A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura
Public ClinicalTrials.gov record NCT01071954. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura (ITP)
Study identification
- NCT ID
- NCT01071954
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Amgen
- Industry
- Enrollment
- 66 participants
Conditions and interventions
Conditions
Interventions
- Romiplostim Biological
Biological
Eligibility (public fields only)
- Age range
- 1 Year and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 29, 2009
- Primary completion
- Jan 11, 2017
- Completion
- Jan 11, 2017
- Last update posted
- Jan 17, 2020
2009 – 2017
United States locations
- U.S. sites
- 24
- U.S. states
- 18
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Orange | California | 92868 | — |
| Research Site | San Diego | California | 92123 | — |
| Research Site | Washington D.C. | District of Columbia | 20010 | — |
| Research Site | Atlanta | Georgia | 30322 | — |
| Research Site | Chicago | Illinois | 60611 | — |
| Research Site | Peoria | Illinois | 61615 | — |
| Research Site | Indianapolis | Indiana | 46260 | — |
| Research Site | Iowa City | Iowa | 52242 | — |
| Research Site | Louisville | Kentucky | 40202 | — |
| Research Site | New Orleans | Louisiana | 70118 | — |
| Research Site | Detroit | Michigan | 48201 | — |
| Research Site | Kansas City | Missouri | 64108 | — |
| Research Site | Omaha | Nebraska | 68114 | — |
| Research Site | Las Vegas | Nevada | 89109 | — |
| Research Site | New Brunswick | New Jersey | 08901 | — |
| Research Site | New York | New York | 10016 | — |
| Research Site | New York | New York | 10021 | — |
| Research Site | Cincinnati | Ohio | 45229 | — |
| Research Site | Columbus | Ohio | 43205 | — |
| Research Site | Pittsburgh | Pennsylvania | 15224 | — |
| Research Site | Nashville | Tennessee | 37232 | — |
| Research Site | Dallas | Texas | 75390 | — |
| Research Site | Fort Worth | Texas | 76104 | — |
| Research Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01071954, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 17, 2020 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01071954 live on ClinicalTrials.gov.